ANRO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
29.1M
+7.3%
27.1M
+59.1%
17.1M
+14.1%
15.0M
-20.0%
18.7M
R&D
22.1M
+8.9%
20.3M
+69.2%
12.0M
+14.0%
10.5M
-19.8%
13.1M
SG&A
7.0M
+2.6%
6.8M
+35.3%
5.1M
+14.3%
4.4M
-20.4%
5.6M
Operating Income
-29129000
-7.3%
-27138000
-59.1%
-17055000
-14.1%
-14951000
+20.0%
-18682000
EBITDA
-28945000
-7.4%
-26954000
-59.5%
-16898000
-14.3%
-14787000
+20.1%
-18513000
Net Income
-27638000
-5.3%
-26237000
-62.1%
-16182000
-14.1%
-14181000
+19.9%
-17706000
EPS (Basic)
$-0.65
+18.8%
$-0.80
-70.2%
$-0.47
+9.6%
$-0.52
+20.0%
$-0.65
EPS (Diluted)
$-0.65
+18.8%
$-0.80
-70.2%
$-0.47
+9.6%
$-0.52
+20.0%
$-0.65
Shares (Diluted)
42.8M
+30.2%
32.9M
-3.8%
34.2M
+26.1%
27.1M
+0.1%
27.1M
Alto Neuroscience (ANRO) โ€” Financials